AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10437990 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose methadone (mean dose 211 mg/d, range 110‐780 mg/d)
Number of subjects: 164
Study 10437990 — intervention group
Group type: COMPARATOR
Intervention: Control group (mean dose 65 mg/d)
Number of subjects: 164
Study 7495043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 22
Study 7495043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2406861 — intervention group
Group type: COMPARATOR
Intervention: Bismuth subsalicylate (BSS)
Number of subjects: 0
Study 2406861 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0
Study 2406861 — intervention group
Group type: COMPARATOR
Intervention: Systemic antimicrobial agents
Number of subjects: 0
Study 6986243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine with antacid therapy
Number of subjects: 27
Study 6986243 — intervention group
Group type: COMPARATOR
Intervention: Antacids alone
Number of subjects: 27
Study 6986243 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cimetidine with antacids
Number of subjects: 27
Study 31765932 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-group based intervention (n=206)
Number of subjects: 402
Study 31765932 — intervention group
Group type: COMPARATOR
Intervention: Self-management control group (n=196)
Number of subjects: 402
Study 31765932 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-group based intervention
Number of subjects: 402
Study 29480853 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - induced by 4 times of 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper arm, followed by 5-min intervals of reperfusion at 1 hour before PCI therapy.
Number of subjects: 161
Study 29480853 — intervention group
Group type: COMPARATOR
Intervention: Control group - an uninflated cuff around the arm.
Number of subjects: 161
Study 27172434 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal T gel (1.25 g, 2.5 g, 5.0 g, 10 g, or 15 g daily) plus acyline injections every 2 weeks
Number of subjects: 62
Study 27172434 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections and transdermal gel
Number of subjects: 62
Study 25209519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozenoxacin 1% ointment (single doses)
Number of subjects: 0
Study 25209519 — intervention group
Group type: COMPARATOR
Intervention: Ozenoxacin 1% ointment (multiple doses)
Number of subjects: 0
Study 25209519 — intervention group
Group type: COMPARATOR
Intervention: Ozenoxacin 2% cream (multiple doses)
Number of subjects: 0
Study 25209519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozenoxacin 2% cream (multiple doses on intact and abraded skin)
Number of subjects: 0
Study 23000583 — intervention group
Group type: EXPERIMENTAL
Intervention: LAB group (LAB‐G)
Number of subjects: 15
Study 23000583 — intervention group
Group type: EXPERIMENTAL
Intervention: LAB with lactose group (L‐LAB‐G)
Number of subjects: 15
Study 23000583 — intervention group
Group type: COMPARATOR
Intervention: Control group (C‐G)
Number of subjects: 15
Study 20362902 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer adhesive (Fuji I)
Number of subjects: 25
Study 20362902 — intervention group
Group type: COMPARATOR
Intervention: Composite resin adhesive (Transbond XT)
Number of subjects: 25
Study 18156660 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-protein supplement (120 kcal, 30 g protein)
Number of subjects: 17
Study 18156660 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric placebo
Number of subjects: 17
Study 18156660 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 17
Study 15726879 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg oral dose)
Number of subjects: 24
Study 15726879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12466928 — intervention group
Group type: EXPERIMENTAL
Intervention: Macro-adjustments in response to the relative probability of conflict trials
Number of subjects: 0
Study 12466928 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-adjustments invoked by the commission of incidental errors
Number of subjects: 0
Study 12466928 — intervention group
Group type: EXPERIMENTAL
Intervention: High probability of conflict trials
Number of subjects: 0
Study 10403033 — intervention group
Group type: EXPERIMENTAL
Intervention: CPRV (n = 163)
Number of subjects: 330
Study 10403033 — intervention group
Group type: COMPARATOR
Intervention: PVRV (n = 167)
Number of subjects: 330
Study 7805119 — intervention group
Group type: EXPERIMENTAL
Intervention: Consupren (Czech preparation of cyclosporin A)
Number of subjects: 5
Study 3182882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ender pins
Number of subjects: 100
Study 3182882 — intervention group
Group type: COMPARATOR
Intervention: Compression hip-screw
Number of subjects: 100
Study 31189497 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration
Number of subjects: 247
Study 31189497 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 247
Study 29649954 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal (RP) approach
Number of subjects: 0
Study 29649954 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal (TP) approach
Number of subjects: 0
Study 29649954 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal clamp position
Number of subjects: 0
Study 29649954 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamp position inferior to the superior mesenteric artery
Number of subjects: 0
Study 29649954 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal function and mortality
Number of subjects: 0
Study 29234745 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive abutment group (immediate loading)
Number of subjects: 80
Study 29234745 — intervention group
Group type: COMPARATOR
Intervention: Repeated abutment changes group (delayed loading)
Number of subjects: 80
Study 25906754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rich in polyphenols
Number of subjects: 86
Study 25906754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rich in LCn3
Number of subjects: 86
Study 25906754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rich in LCn3 and polyphenols
Number of subjects: 86
Study 24499699 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherical IOL implantation
Number of subjects: 96
Study 24499699 — intervention group
Group type: COMPARATOR
Intervention: Traditional sphere IOL implantation
Number of subjects: 96
Study 21402400 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled Hispanic women
Number of subjects: 0
Study 21402400 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropout rate
Number of subjects: 0
Study 21402400 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for active refusal
Number of subjects: 0
Study 19014072 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for OSA
Number of subjects: 30
Study 19014072 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 30
Study 16764983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-to-mouth ventilation (MMV)
Number of subjects: 70
Study 16764983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-to-pocket-mask ventilation (MPV)
Number of subjects: 70
Study 16764983 — intervention group
Group type: COMPARATOR
Intervention: Mouth-to-face-shield ventilation (MFV)
Number of subjects: 70
Study 12694632 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including a workshop in evidence‐based public health, a newsletter, access to a specially designed information service, relevant databases, and an electronic discussion list.
Number of subjects: 148
Study 12694632 — intervention group
Group type: COMPARATOR
Intervention: Control group received a letter declaring access to library services.
Number of subjects: 148
Study 10885237 — intervention group
Group type: EXPERIMENTAL
Intervention: Drip-infusion of Diprivan (1% propofol emulsion)
Number of subjects: 28
Study 10885237 — intervention group
Group type: COMPARATOR
Intervention: Syringe-pump administration of Diprivan (1% propofol emulsion)
Number of subjects: 28
Study 8813310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 204
Study 8813310 — intervention group
Group type: COMPARATOR
Intervention: Endometrial ablation
Number of subjects: 204
Study 8316057 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplementation (600 mg/d of garlic powder for two weeks)
Number of subjects: 10
Study 8316057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3712428 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-prompt group
Number of subjects: 83
Study 3712428 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-prompt group
Number of subjects: 83
Study 3712428 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 30676223 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Leap Balance Test (DLBT)
Number of subjects: 36
Study 30676223 — intervention group
Group type: COMPARATOR
Intervention: Star Excursion Balance Test (SEBT)
Number of subjects: 36
Study 29371672 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol
Number of subjects: 0
Study 29371672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29371672 — intervention group
Group type: COMPARATOR
Intervention: No alcohol (sober)
Number of subjects: 0
Study 27903994 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplement, 1000 mg/d for 6 weeks
Number of subjects: 66
Study 27903994 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules a day) for 6 weeks
Number of subjects: 66
Study 25661412 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal suction
Number of subjects: 122
Study 25661412 — intervention group
Group type: COMPARATOR
Intervention: No suction
Number of subjects: 122
Study 23895165 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 combined with selenium
Number of subjects: 443
Study 23895165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 20819135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low bulb obturators
Number of subjects: 13
Study 20819135 — intervention group
Group type: COMPARATOR
Intervention: High bulb obturators
Number of subjects: 13
Study 19068205 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker bisoprolol (n=55)
Number of subjects: 110
Study 19068205 — intervention group
Group type: COMPARATOR
Intervention: Routine drugs (ACE Inhibitors, diuretics, vasodilator drugs) (n=55)
Number of subjects: 110
Study 16897997 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (2-week administration followed by 1-week rest)
Number of subjects: 0
Study 16897997 — intervention group
Group type: COMPARATOR
Intervention: UFT (4-week administration followed by 2-week rest)
Number of subjects: 0
Study 12627181 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 21
Study 12627181 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (HFD)
Number of subjects: 21
Study 12627181 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine supplementation
Number of subjects: 21
Study 10709813 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (patients with daytime complaints)
Number of subjects: 16
Study 10709813 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (patients without daytime complaints)
Number of subjects: 16
Study 10709813 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study 9663830 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (600-2400 microg/day)
Number of subjects: 18
Study 9663830 — intervention group
Group type: COMPARATOR
Intervention: Single-dose misoprostol (400 microg)
Number of subjects: 18
Study 8409784 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation for osseous pain
Number of subjects: 0
Study 8409784 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation for soft tissue pain
Number of subjects: 0
Study 8409784 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual observation
Number of subjects: 0
Study 8409784 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface EMG measurements
Number of subjects: 0
Study 8409784 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermothermograph measurements
Number of subjects: 0
Study 8409784 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional index of lumbar abnormality
Number of subjects: 0
Study 3947108 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ PSK in alternate doses (Group B)
Number of subjects: 168
Study 3947108 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ + PSK in alternate doses (Group D)
Number of subjects: 168
Study 3947108 — intervention group
Group type: COMPARATOR
Intervention: CQ intermittently (Group A)
Number of subjects: 168
Study 3947108 — intervention group
Group type: COMPARATOR
Intervention: Controls (Group C)
Number of subjects: 168
Study 3947108 — intervention group
Group type: COMPARATOR
Intervention: Controls (Group E)
Number of subjects: 168
Study 30340619 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 75
Study 30340619 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 75
Study 30340619 — intervention group
Group type: COMPARATOR
Intervention: Wellness education (active control)
Number of subjects: 75
Study 27485109 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sequencing (DS) of BCR-ABL1
Number of subjects: 51
Study 24646123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package including mobilization of family support, emergency funds, transport options, training for health workers, and security provisions.
Number of subjects: 5000
Study 24646123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention package
Number of subjects: 5000
Study 24646123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention package)
Number of subjects: 5000
Study 22182254 — intervention group
Group type: COMPARATOR
Intervention: Normal weight women
Number of subjects: 112
Study 22182254 — intervention group
Group type: COMPARATOR
Intervention: Overweight women
Number of subjects: 112
Study 22182254 — intervention group
Group type: COMPARATOR
Intervention: Obese women
Number of subjects: 112
Study 22182254 — intervention group
Group type: COMPARATOR
Intervention: Normal weight individuals
Number of subjects: 112
Study 22182254 — intervention group
Group type: COMPARATOR
Intervention: Overweight individuals
Number of subjects: 112
Study 22182254 — intervention group
Group type: COMPARATOR
Intervention: Obese individuals
Number of subjects: 112
Study 22182254 — intervention group
Group type: EXPERIMENTAL
Intervention: Type II sarcopenic individuals
Number of subjects: 112
Study 19909829 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronate injections (2 mg every 2 months, 3 mg every 3 months)
Number of subjects: 1395
Study 19909829 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronate (3 mg)
Number of subjects: 1395
Study 19909829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate (2.5 mg daily)
Number of subjects: 1395
Study 19909829 — intervention group
Group type: COMPARATOR
Intervention: Oral or IV placebo
Number of subjects: 1395
Study 18822932 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system (CGMS) for 3 days every 2 weeks for 6 months
Number of subjects: 32
Study 18822932 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with CGMS
Number of subjects: 32
Study 18822932 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide blood glucose fluctuations
Number of subjects: 32
Study 18822932 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic interventions aimed at reducing fluctuations
Number of subjects: 32
Study 16037147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 115
Study 16037147 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 115
Study 12459940 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg/day for 48 weeks)
Number of subjects: 235
Study 12459940 — intervention group
Group type: COMPARATOR
Intervention: Etidronate (200 mg/day for 2 weeks followed by 10-week medication-free periods)
Number of subjects: 235
Study 12459940 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 235
Study 12459940 — intervention group
Group type: COMPARATOR
Intervention: Etidronate
Number of subjects: 235
Study 10673950 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum patient positioning for left‐sided tumours
Number of subjects: 26
Study 10673950 — intervention group
Group type: COMPARATOR
Intervention: Standard patient treatment position for left‐sided tumours
Number of subjects: 26
Study 10673950 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional planning with optimum treatment position for left‐sided tumours
Number of subjects: 26
Study 10673950 — intervention group
Group type: COMPARATOR
Intervention: Standard glancing field set-up for left‐sided tumours
Number of subjects: 26
Study 10673950 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum patient positioning for right‐sided tumours
Number of subjects: 26
Study 9180955 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux assessment
Number of subjects: 10
Study 9180955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function assessment
Number of subjects: 10
Study 9180955 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship assessment between gastroesophageal reflux and pulmonary damage
Number of subjects: 10
Study 9180955 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric acid secretion assessment
Number of subjects: 10
Study 9180955 — intervention group
Group type: EXPERIMENTAL
Intervention: Steatorrhea assessment
Number of subjects: 10
Study 1503823 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160 vaccination
Number of subjects: 10
Study 1503823 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 3900301 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 715
Study 3900301 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-levamisole
Number of subjects: 715
Study 3900301 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-levamisole-BCG
Number of subjects: 715
Study 3900301 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 715
Study 3900301 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy alone
Number of subjects: 715
Study 31383385 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral ibuprofen
Number of subjects: 225
Study 31383385 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral ibuprofen
Number of subjects: 225
Study 31383385 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral ibuprofen
Number of subjects: 225
Study 29220345 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐provisional stenting
Number of subjects: 146
Study 29220345 — intervention group
Group type: COMPARATOR
Intervention: mini‐crush technique
Number of subjects: 146
Study 26172529 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 522
Study 26172529 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study 24613450 — intervention group
Group type: COMPARATOR
Intervention: Weekly oral alendronate (70 mg)
Number of subjects: 101
Study 24613450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (1-time 5 mg)
Number of subjects: 101
Study 22588319 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 382
Study 22588319 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 382
Study 19909947 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (1.5 mg) administered orally
Number of subjects: 27
Study 19909947 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (1.5 mg) administered vaginally
Number of subjects: 27
Study 19909947 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 27
Study 18663546 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 22
Study 15769243 — intervention group
Group type: EXPERIMENTAL
Intervention: Negotiators who reached an impasse in prior negotiations
Number of subjects: 0
Study 15769243 — intervention group
Group type: COMPARATOR
Intervention: Negotiators who reached an initial agreement in prior negotiations
Number of subjects: 0
Study 11826199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 10519745 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam sedation with lignocaine 2%, adrenaline 1:50,000, and vasopressin 0.25 IU
Number of subjects: 75
Study 10519745 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 2%, adrenaline 1:50,000, and vasopressin 0.25 IU alone (anesthetic group)
Number of subjects: 75
Study 7500174 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy nutrient dense supplement provided by a dietitian
Number of subjects: 50
Study 7500174 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving visits only
Number of subjects: 50
Study 1771281 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 40
Study 1771281 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg)
Number of subjects: 40
Study 6349453 — intervention group
Group type: EXPERIMENTAL
Intervention: Real peritoneal dialysis (48 hours weekly, 1.5-hour cycle times, 2-litre exchanges by machine)
Number of subjects: 5
Study 6349453 — intervention group
Group type: COMPARATOR
Intervention: Sham peritoneal dialysis (recycling the same 2 litres of 1.5% continuous ambulatory peritoneal dialysis fluid, 1.5-hour cycle times for 48 hours weekly)
Number of subjects: 5
Study 30956021 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video after face-to-face education
Number of subjects: 60
Study 30956021 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face education only
Number of subjects: 60
Study 29710059 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum-containing thickener
Number of subjects: 0
Study 29710059 — intervention group
Group type: COMPARATOR
Intervention: Starch-based thickener
Number of subjects: 0